Oramed Pharmaceuticals (ORMP) Cash from Financing Activities (2010 - 2026)

Oramed Pharmaceuticals has reported Cash from Financing Activities for 17 years, with the latest figure at -$10.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$10.4 million; the trailing twelve-month figure through Mar 2026 stood at -$15.9 million (changed N/A YoY), and the FY2025 full-year result was -$4.7 million, up 90.89% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$10.4 million, down from -$4.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $74.5 million in Q3 2023, with the low at -$30.6 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged -$286642.9 across 5 years, with a median of -$778000.0 in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 1628.45% — and 2024, when it tumbled 881.89%.
• Oramed Pharmaceuticals' Cash from Financing Activities stood at $4.2 million in 2022, then tumbled by 698.8% to -$25.0 million in 2023, then surged by 95.22% to -$1.2 million in 2024, then tumbled by 235.48% to -$4.0 million in 2025, then slumped by 158.52% to -$10.4 million in 2026.
• The last three Cash from Financing Activities figures came in at -$10.4 million (Q1 2026), -$4.0 million (Q4 2025), and -$361000.0 (Q3 2025), per Business Quant data.